Integra Lifesciences Holdings Stock Current Valuation

IART Stock

USD 24.54 0.84 3.54%

Valuation analysis of Integra LifeSciences helps investors to measure Integra LifeSciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 442.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop 10.86 in 2024. Fundamental drivers impacting Integra LifeSciences' valuation include:

Price Book

1.2019

Enterprise Value

3.6 B

Enterprise Value Ebitda

18.8564

Price Sales

1.21

Forward PE

9.5147

Undervalued

Today

24.54

Please note that Integra LifeSciences' price fluctuation is not too volatile at this time. Calculation of the real value of Integra LifeSciences is based on 3 months time horizon. Increasing Integra LifeSciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.

Buy or Sell Advice Valuation Matrix

Integra LifeSciences' intrinsic value may or may not be the same as its current market price of 24.54, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.

Historical

Market 24.54

Real 29.77

Target 46.89

Hype 24.17

The intrinsic value of Integra LifeSciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integra LifeSciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.

22.09

Downside

29.77

Real Value

Target Odds

Above Odds

Below Odds

33.81

Upside

Estimating the potential upside or downside of Integra LifeSciences Holdings helps investors to forecast how Integra stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integra LifeSciences more accurately as focusing exclusively on Integra LifeSciences' fundamentals will not take into account other important factors:

Earnings

Estimates (0)

Low	Projected	High
0.61	0.86	0.62

Details

Hype

Prediction

Low	Estimated	High
20.13	24.17	28.21

Details

13 Analysts

Consensus

Low	Target Price	High
42.67	46.89	52.05

Details

Integra LifeSciences Holdings Company Current Valuation Analysis

Integra LifeSciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Integra LifeSciences Current Valuation

3.61 B

Most of Integra LifeSciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integra LifeSciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Integra Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Integra LifeSciences is extremely important. It helps to project a fair market value of Integra Stock properly, considering its historical fundamentals such as Current Valuation. Since Integra LifeSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Integra LifeSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Integra LifeSciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.94	0.83	0.86	0.96	0.99	0.96	0.97	0.68	0.02	0.86	0.86	-0.04	0.94	0.57	0.99	-0.67	0.89	0.87	0.17	-0.03	0.84	0.69	0.77	0.54
Total Stockholder Equity	0.97		0.84	0.87	0.82	0.92	0.92	0.96	0.92	0.7	0.05	0.85	0.77	-0.11	0.94	0.45	0.95	-0.52	0.79	0.91	0.16	-0.01	0.87	0.73	0.82	0.55
Net Debt	0.94	0.84		0.69	0.88	0.95	0.98	0.84	0.96	0.57	-0.03	0.8	0.9	0.08	0.88	0.68	0.96	-0.84	0.94	0.74	0.19	-0.07	0.72	0.49	0.56	0.48
Retained Earnings	0.83	0.87	0.69		0.71	0.74	0.78	0.86	0.71	0.88	-0.1	0.56	0.54	-0.37	0.82	0.41	0.79	-0.21	0.59	0.72	0.02	-0.15	0.7	0.88	0.85	0.76
Accounts Payable	0.86	0.82	0.88	0.71		0.93	0.86	0.78	0.85	0.48	-0.15	0.73	0.75	-0.02	0.88	0.56	0.87	-0.63	0.78	0.7	0.04	-0.19	0.72	0.44	0.49	0.48
Net Receivables	0.96	0.92	0.95	0.74	0.93		0.96	0.89	0.96	0.53	0.01	0.86	0.86	-0.01	0.96	0.59	0.97	-0.72	0.87	0.81	0.17	-0.03	0.8	0.5	0.59	0.46
Total Liab	0.99	0.92	0.98	0.78	0.86	0.96		0.93	0.98	0.65	0.01	0.85	0.9	0.02	0.92	0.64	0.99	-0.76	0.94	0.82	0.18	-0.04	0.8	0.63	0.71	0.52
Total Current Assets	0.96	0.96	0.84	0.86	0.78	0.89	0.93		0.88	0.69	0.0	0.81	0.81	-0.18	0.9	0.51	0.92	-0.51	0.83	0.84	0.03	-0.05	0.82	0.76	0.86	0.53
Intangible Assets	0.97	0.92	0.96	0.71	0.85	0.96	0.98	0.88		0.58	0.05	0.88	0.9	0.11	0.9	0.61	0.99	-0.81	0.93	0.84	0.27	0.0	0.81	0.56	0.66	0.45
Short Term Investments	0.68	0.7	0.57	0.88	0.48	0.53	0.65	0.69	0.58		-0.11	0.38	0.38	-0.2	0.62	0.26	0.66	-0.14	0.48	0.65	0.04	-0.16	0.6	0.87	0.82	0.82
Short Term Debt	0.02	0.05	-0.03	-0.1	-0.15	0.01	0.01	0.0	0.05	-0.11		0.31	0.03	0.32	0.05	0.24	0.03	-0.06	0.0	-0.01	0.5	1.0	-0.09	-0.04	-0.02	-0.1
Common Stock	0.86	0.85	0.8	0.56	0.73	0.86	0.85	0.81	0.88	0.38	0.31		0.9	0.21	0.8	0.59	0.87	-0.7	0.87	0.84	0.25	0.27	0.84	0.39	0.59	0.13
Long Term Debt	0.86	0.77	0.9	0.54	0.75	0.86	0.9	0.81	0.9	0.38	0.03	0.9		0.09	0.76	0.74	0.87	-0.84	0.98	0.76	0.17	-0.01	0.75	0.38	0.54	0.11
Treasury Stock	-0.04	-0.11	0.08	-0.37	-0.02	-0.01	0.02	-0.18	0.11	-0.2	0.32	0.21	0.09		-0.15	-0.13	0.04	-0.39	0.16	-0.04	-0.04	0.33	0.12	-0.29	-0.19	-0.2
Property Plant Equipment	0.94	0.94	0.88	0.82	0.88	0.96	0.92	0.9	0.9	0.62	0.05	0.8	0.76	-0.15		0.56	0.93	-0.56	0.77	0.83	0.25	0.01	0.76	0.57	0.63	0.56
Current Deferred Revenue	0.57	0.45	0.68	0.41	0.56	0.59	0.64	0.51	0.61	0.26	0.24	0.59	0.74	-0.13	0.56		0.58	-0.66	0.71	0.38	0.46	0.22	0.24	0.25	0.24	0.12
Good Will	0.99	0.95	0.96	0.79	0.87	0.97	0.99	0.92	0.99	0.66	0.03	0.87	0.87	0.04	0.93	0.58		-0.73	0.9	0.86	0.2	-0.02	0.84	0.63	0.72	0.54
Net Tangible Assets	-0.67	-0.52	-0.84	-0.21	-0.63	-0.72	-0.76	-0.51	-0.81	-0.14	-0.06	-0.7	-0.84	-0.39	-0.56	-0.66	-0.73		-0.86	-0.48	-0.31	-0.04	-0.47	-0.1	-0.2	-0.08
Long Term Debt Total	0.89	0.79	0.94	0.59	0.78	0.87	0.94	0.83	0.93	0.48	0.0	0.87	0.98	0.16	0.77	0.71	0.9	-0.86		0.76	0.13	-0.04	0.77	0.46	0.6	0.24
Capital Surpluse	0.87	0.91	0.74	0.72	0.7	0.81	0.82	0.84	0.84	0.65	-0.01	0.84	0.76	-0.04	0.83	0.38	0.86	-0.48	0.76		0.23	-0.06	0.93	0.58	0.76	0.33
Deferred Long Term Liab	0.17	0.16	0.19	0.02	0.04	0.17	0.18	0.03	0.27	0.04	0.5	0.25	0.17	-0.04	0.25	0.46	0.2	-0.31	0.13	0.23		0.5	-0.08	-0.02	-0.08	0.02
Short Long Term Debt	-0.03	-0.01	-0.07	-0.15	-0.19	-0.03	-0.04	-0.05	0.0	-0.16	1.0	0.27	-0.01	0.33	0.01	0.22	-0.02	-0.04	-0.04	-0.06	0.5		-0.14	-0.1	-0.08	-0.13
Long Term Investments	0.84	0.87	0.72	0.7	0.72	0.8	0.8	0.82	0.81	0.6	-0.09	0.84	0.75	0.12	0.76	0.24	0.84	-0.47	0.77	0.93	-0.08	-0.14		0.55	0.76	0.3
Net Invested Capital	0.69	0.73	0.49	0.88	0.44	0.5	0.63	0.76	0.56	0.87	-0.04	0.39	0.38	-0.29	0.57	0.25	0.63	-0.1	0.46	0.58	-0.02	-0.1	0.55		0.93	0.75
Net Working Capital	0.77	0.82	0.56	0.85	0.49	0.59	0.71	0.86	0.66	0.82	-0.02	0.59	0.54	-0.19	0.63	0.24	0.72	-0.2	0.6	0.76	-0.08	-0.08	0.76	0.93		0.57
Capital Stock	0.54	0.55	0.48	0.76	0.48	0.46	0.52	0.53	0.45	0.82	-0.1	0.13	0.11	-0.2	0.56	0.12	0.54	-0.08	0.24	0.33	0.02	-0.13	0.3	0.75	0.57

Click cells to compare fundamentals

Integra Current Valuation Historical Pattern

Today, most investors in Integra LifeSciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Integra LifeSciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Integra LifeSciences current valuation as a starting point in their analysis.

Integra LifeSciences Current Valuation

Timeline

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Competition

Predict Integra LifeSciences

Enterprise Value Over Time

In accordance with the recently published financial statements, Integra LifeSciences Holdings has a Current Valuation of 3.61 B. This is 74.9% lower than that of the Health Care Equipment & Supplies sector and 70.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 78.31% higher than that of the company.

Integra Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integra LifeSciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics of similar companies.

Integra LifeSciences is currently under evaluation in current valuation category among its peers.

Integra LifeSciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Integra LifeSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Integra LifeSciences' managers, analysts, and investors.

Environmental

Governance

Social

Integra Fundamentals

	Return On Equity	-0.0042
	Return On Asset	0.0302
	Profit Margin	(0) %
	Operating Margin	0.07 %
	Current Valuation	3.61 B
	Shares Outstanding	77.16 M
	Shares Owned By Insiders	3.21 %
	Shares Owned By Institutions	93.25 %
	Number Of Shares Shorted	4.1 M
	Price To Earning	26.94 X
	Price To Book	1.20 X
	Price To Sales	1.21 X
	Revenue	1.54 B
	Gross Profit	982.03 M
	EBITDA	274.01 M
	Net Income	67.74 M
	Cash And Equivalents	451.52 M
	Cash Per Share	5.41 X
	Total Debt	1.68 B
	Debt To Equity	1.03 %
	Current Ratio	3.85 X
	Book Value Per Share	19.73 X
	Cash Flow From Operations	139.96 M
	Short Ratio	4.10 X
	Earnings Per Share	(0.09) X
	Price To Earnings To Growth	0.79 X
	Target Price	28.11
	Number Of Employees	3.95 K
	Beta	1.08
	Market Capitalization	1.89 B
	Total Asset	3.78 B
	Retained Earnings	946.86 M
	Working Capital	751.06 M
	Current Asset	438.5 M
	Current Liabilities	139.13 M
	Net Asset	3.78 B

About Integra LifeSciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Integra LifeSciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Integra Lifesciences Holdings Stock Current Valuation

Integra LifeSciences Holdings Company Current Valuation Analysis

Enterprise Value

Market Cap + Debt

-

Cash

Current Integra LifeSciences Current Valuation

Integra Current Valuation Driver Correlations

Integra Current Valuation Historical Pattern

Integra Current Valuation Peer Comparison

Integra LifeSciences ESG Sustainability

Integra Fundamentals

About Integra LifeSciences Fundamental Analysis

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Integra Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY